Fig. 5

Effect of DMC on the status of oxidative stress and the activities of SOD, GPx, and CAT in the cerebral cortex and hippocampus of rats with CCI (n = 5). DMC decreased the MDA levels in the cerebral cortex (a) and hippocampus (b). * p <0.05, ** p <0.01 compared to the Sham group; ^#p <0.05, ^##p <0.01 compared to the 2-VO group. c DMC reduced the SOD activity in the cerebral cortex of rats with CCI. * p <0.05 compared to the Sham group; ^#p <0.05 compared to the 2-VO group. d No significant change in the SOD levels was found in the hippocampus of rats with CCI. DMC enhanced GPx activity in the cerebral cortex (e) and hippocampus (f) of rats with CCI. * p <0.05 compared to the Sham group; ^#p <0.05, compared to the 2-VO group. DMC elevated CAT activity in the cerebral cortex (g) and hippocampus (h). * p <0.05, ** p <0.01 compared to the Sham group; ^#p <0.05, compared to the 2-VO group. CCI: chronic cerebral ischemia; DMC: Daming capsule